RecruitMe Clinical Trial

CREAD STUDY: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMERS DISEASE
A study for patients with Alzheimer's disease using study drug crenezumab
Sponsor:Genentech, Inc.
Enrolling:Male and Female Patients
Age Range:Between 50 and 85 years old
IRB Number:AAAQ6304
U.S. Government ID:NCT02670083
Contact: Katrina Cuasay: 212-305-2077 / kc2305@columbia.edu
Additional Study Information:

The purpose of this study is to test the effects of an investigational drug called crenezumab for the treatment of Alzheimers disease. This study will use MRI scans to look at the effects of this treatment on the brain. This study will be conducted in many centers around the world, and it is important that the MRI scans are always performed in a similar fashion throughout the study. We hope that the use of MRI scanning will provide us with a better understanding of how the drug is working in changing the course of Alzheimers disease. There are rigorous quality control processes in place to ensure that the measurements are consistent both across imaging centers and for the duration of the study. An important part of the quality control process involves comparing images from MRI brain scans to ensure that the parameters used by the scanner have not changed. You are being asked to assist with these quality control processes by volunteering to have an MRI brain scan for the purposes of determining scanner image quality for Study BN29552.

This study is closed
Investigator
Lawrence Honig, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Katrina Cuasay
Email: kc2305@columbia.edu
Phone: 212-305-2077